Hikma Pharmaceuticals' first-half results showed solid growth in its Middle East and North Africa branded division offsetting flat injectables sales, as the group kept its full-year guidance unchanged.

Hikma Pharmaceuticals Plc (LSE:HIK), the London-listed generic and specialty drugmaker, has kept investors focused on execution in 2026, with management emphasising steady delivery across its injectables, branded and generics operations. Its interim results, published on 6 August 2026, showed modest top-line growth, firmer profitability and an unchanged full-year outlook, leaving the FTSE 250 group on course to meet the targets it set out in February.

A tale of three divisions

Group revenue for the six months to 30 June 2026 rose 4% to $1.73bn, or 3% at constant currency. Core operating profit increased 9% to $405m, and core earnings per share rose 5% to 128 cents. Reported operating profit rose 30% to $336m, though that comparison was flattered by a legal settlement charge in the first half of 2025. Cash flow from operations improved by a third to $214m.

The standout performer was the Branded business, which sells medicines across the Middle East and North Africa. Revenue there climbed 15% to $502m and core operating profit rose 23%, lifting the division's core margin to 32.5%. Hikma (LSE:HIK) signed ten new partnership agreements in the region during the period, adding to its pipeline of licensed products.

Injectables, the group's largest division, delivered flat revenue of $685m, while core operating profit fell 8% as the company increased sales and marketing spending on its US commercial platform. The core margin for the unit was 27.6%. The Hikma Rx generics business also reported flat revenue of $520m, but its core operating profit rose 16% to give a margin of 20.6%.

Chief executive Said Darwazah described the period as a solid first half and said the group was building agility while directing capital towards areas where it has a sustainable competitive advantage. Research and development spending rose 18%, with 48 product submissions and 43 launches in the half.

Guidance, dividend and buyback

Hikma reiterated guidance for 2026 revenue growth of 2% to 4% at constant currency and core operating profit of $720m to $770m. The interim dividend was raised 6% to 38 cents per share. The company has also been working through a $250m share buyback, with around $227m of shares repurchased by early August.

Net debt relative to core EBITDA rose to 1.9 times at the end of June from 1.6 times at the end of 2025, reflecting the buyback and continued investment. The market reaction was positive. The shares rose about 10% to around 1,733p in early afternoon trading on the day of the results, as investors welcomed the margin improvement and the confirmation of guidance. That move left the stock well above the level of roughly 1,377p recorded in late April, when the company issued its first-quarter trading update.

Earlier, in April, the company had said demand in the Middle East remained resilient despite regional tensions, and that all three businesses had started the year well. That resilience has been a key support for the shares, given the volatility in the US generics market and ongoing debate over pharmaceutical pricing and trade policy in the United States.

Investors will be watching for any trading commentary before the full-year results, with attention likely to fall on injectables demand in the US and whether the Branded division can sustain its momentum into the second half.